
Sun Pharma Aisling doxorubicin injection recalled for glass particles in vials
Sun Pharmaceutical is recalling one batch of Aisling doxorubicin hydrochloride liposome injection (a cancer medication) because glass particles were found in some vials during manufacturing. Glass particles in injectable medications can cause local tissue damage, blood vessel blockage, or blood clots if injected into the bloodstream. No patient injuries have been reported so far.
From the FDA notice · Read the official notice ↗
What to do
- If you are a hospital, pharmacy, or healthcare provider: stop using batch HAG2581B (expiration 05/31/2027) and return it or discard it safely.
- If you have received this medication or used it: contact your doctor or healthcare provider immediately.
- Report any problems or side effects to the FDA's MedWatch program at www.fda.gov/medwatch/report.htm or call 1-800-332-1088.
- For recall questions, contact the recall processor Inmar Inc. at 855-745-9357 (Monday–Friday, 8:30 a.m.–5:00 p.m. ET) or rxrecalls@inmar.com.
Is yours affected?
Compare your label or packaging with the recalled product.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Illnesses reported
- None reported
In the FDA's words
FOR IMMEDIATE RELEASE MUMBAI, INDIA and PRINCETON, NJ - May 13, 2026 – Sun Pharma is voluntarily recalling within the U.S. to the hospital/user level, one batch of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, Lot # HAG2581B, Expiration 05/2027 (675 vials). The single batch of 675 vials is being recalled due to the detection of glass particles in some vials during production.
If glass particles are administered intravenously, they may pose a risk to patient safety including local irritation or swelling in response to the foreign material. More serious potential risks could include blockage of blood vessels and life-threatening blood clot events. To date, Sun Pharma has not received any reports of adverse events related to this batch. Sun Pharma has thoroughly investigated the source of the problem and has taken corrective and preventative actions.
Doxorubicin Hydrochloride Liposome Injection is indicated for Ovarian cancer, AIDS Related Kaposi Sarcoma and Multiple Myeloma. The product is packaged in translucent, red liposomal dispersion in 25 mL glass, single-dose vials for NDC 72603-200-01. The affected DOXOrubicin Hydrochloride Liposome Injection batch is Batch HAG2581B, Expiration 05/31/2027. The product can be identified by the label (Aisling Label), each vial is labeled to indicate the name of the product: DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, NDC 72603-200-01 Lot# HAG2581B, Expiration 05/31/2027.
Read the full announcementShow less
Sun Pharma is notifying its distributor and customers by express overnight mail and is arranging for return/replacement etc. of all recalled products.
Distributors/retailers/hospitals/users that have the product should stop using and return to place of purchase or discard the product. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. To report suspected adverse events contact NorthStar Rx LLC at 1-800-206-7821
Customers with questions regarding this recall can contact Inmar Inc. , (Sun Pharma’s recall processor) by 855-745-9357, Monday through Friday between 8:30 am and 5:00 pm, U.S. Eastern Time, or via rxrecalls@inmar.com .
Inmar, Inc.
3845 Grand Lakes Way Grand Prairie, TX 75050 Tel. 855-745-9357 Fax. 817-868-5362 Email: rxrecalls@inmar.com
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Complete and submit the report Online: www.fda.gov/medwatch/report.htm 1
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm 2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.